Levitan, B., Yuan, Z., Turpie, A. G., Friedman, R. J., Homering, M., Berlin, J. A., . . . DiBattiste, P. M. (2014). Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Dove Medical Press.

Levitan, Bennett, Zhong Yuan, Alexander GG Turpie, Richard J. Friedman, Martin Homering, Jesse A. Berlin, Scott D. Berkowitz, Rachel B. Weinstein, and Peter M. DiBattiste. Benefit–risk Assessment of Rivaroxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty. Dove Medical Press, 2014.

Levitan, Bennett, et al. Benefit–risk Assessment of Rivaroxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty. Dove Medical Press, 2014.